
© 2025 Edison Investment Research
Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
Di | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. ("Biomea" or the "Company") (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, today announced that... ► Artikel lesen | |
Mo | Biomea Fusion, Inc. - 10-K, Annual Report | ||
Mo | Biomea Fusion, Inc.: Biomea Fusion Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights | Mick Hitchcock, Ph.D., appointed Interim Chief Executive OfficerBiomea preparing icovamenib for late-stage clinical developmentMultiple milestones anticipated in 2025 including:FDA meeting anticipated... ► Artikel lesen | |
27.03. | Biomea Fusion, Inc. - 8-K, Current Report | ||
26.03. | Biomea Fusion appoints Mick Hitchcock to succeed Thomas Butler as interim CEO |